In this SOHO Insider roundtable discussion, Charalambos (Babis) Andreadis, MD, MS, professor of clinical medicine at University of California, San Francisco, moderates a discussion on CELLMods in lymphoma.
The panelists include Jason Westin, MD, associate professor in the Department of Lymphoma/Myeloma at University of Texas MD Anderson Cancer Center; Loretta Nastoupil, MD, section chief of indolent lymphoma and director of clinical research at Common Spirit Health; and Swetha Thiruvengadam, MD, assistant clinical professor in the Department of Hematology & Hematopoietic Cell Transplantation at the City of Hope.
In this video, the group discusses the 2025 DLBCL treatment landscape.
“We have gone from having R-CHOP and chemotherapy in the second link to to having an embarrassment of riches, basically a wealth of new drugs coming along,” Dr. Westin said. “Many new drugs have been approved in the relapse/refractory space, including CAR-T cell therapies, bispecifics, some targeted antibody drug conjugates, and now a lot of these drugs are being looked at in the frontline space.”
Watch more videos from this discussion.
This video is being brought to you by an education grant by Bristol Myers Squibb.
